181 related articles for article (PubMed ID: 29655642)
1. Estimating Medicare and Patient Savings From the Use of Bevacizumab for the Treatment of Exudative Age-related Macular Degeneration.
Rosenfeld PJ; Windsor MA; Feuer WJ; Sun SJJ; Frick KD; Swanson EA; Huang D
Am J Ophthalmol; 2018 Jul; 191():135-139. PubMed ID: 29655642
[TBL] [Abstract][Full Text] [Related]
2. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.
Erie JC; Barkmeier AJ; Hodge DO; Mahr MA
Ophthalmology; 2016 Jun; 123(6):1257-62. PubMed ID: 26976701
[TBL] [Abstract][Full Text] [Related]
3. Estimating Public and Patient Savings From Basic Research-A Study of Optical Coherence Tomography in Managing Antiangiogenic Therapy.
Windsor MA; Sun SJJ; Frick KD; Swanson EA; Rosenfeld PJ; Huang D
Am J Ophthalmol; 2018 Jan; 185():115-122. PubMed ID: 29224686
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file.
Brechner RJ; Rosenfeld PJ; Babish JD; Caplan S
Am J Ophthalmol; 2011 May; 151(5):887-895.e1. PubMed ID: 21310390
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal Anti-Vascular Endothelial Growth Factor Cost Savings Achievable with Increased Bevacizumab Reimbursement and Use.
Glasser DB; Parikh R; Lum F; Williams GA
Ophthalmology; 2020 Dec; 127(12):1688-1692. PubMed ID: 32544559
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.
Vottonen P; Kankaanpää E
Acta Ophthalmol; 2016 Nov; 94(7):652-656. PubMed ID: 27481048
[TBL] [Abstract][Full Text] [Related]
7. Treating age-related macular degeneration: comparing the use of two drugs among medicare and veterans affairs populations.
Pershing S; Pal Chee C; Asch SM; Baker LC; Boothroyd D; Wagner TH; Bundorf MK
Health Aff (Millwood); 2015 Feb; 34(2):229-38. PubMed ID: 25646102
[TBL] [Abstract][Full Text] [Related]
8. A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States.
Brown GC; Brown MM; Rapuano SB; Boyer D
Am J Ophthalmol; 2021 Mar; 223():405-429. PubMed ID: 32681907
[TBL] [Abstract][Full Text] [Related]
9. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
[TBL] [Abstract][Full Text] [Related]
10. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration.
Holekamp NM; Liu Y; Yeh WS; Chia Y; Kiss S; Almony A; Kowalski JW
Am J Ophthalmol; 2014 Apr; 157(4):825-833.e1. PubMed ID: 24388973
[TBL] [Abstract][Full Text] [Related]
11. Geographic and Demographic Variation in Use of Ranibizumab Versus Bevacizumab for Neovascular Age-related Macular Degeneration in the United States.
Gower EW; Stein JD; Shekhawat NS; Mikkilineni S; Blachley TS; Pajewski NM
Am J Ophthalmol; 2017 Dec; 184():157-166. PubMed ID: 29106914
[TBL] [Abstract][Full Text] [Related]
12. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
13. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
[TBL] [Abstract][Full Text] [Related]
14. Costs of newly diagnosed neovascular age-related macular degeneration among medicare beneficiaries, 2004-2008.
Qualls LG; Hammill BG; Wang F; Lad EM; Schulman KA; Cousins SW; Curtis LH
Retina; 2013 Apr; 33(4):854-61. PubMed ID: 23296047
[TBL] [Abstract][Full Text] [Related]
15. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
[TBL] [Abstract][Full Text] [Related]
17. [Interest of optical coherence tomography performed immediately before intravitreal injection of anti-VEGF in exudative AMD].
Moyal L; Cohen SY; Pedinielli A; Semoun O; Lalloum F; Jung C; Souied E
J Fr Ophtalmol; 2015 Sep; 38(7):573-9. PubMed ID: 25997681
[TBL] [Abstract][Full Text] [Related]
18. Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of Age-Related Macular Degeneration: An Economic Disparity of Eye Health.
Moreno TA; Kim SJ
Semin Ophthalmol; 2016; 31(4):378-84. PubMed ID: 27116030
[TBL] [Abstract][Full Text] [Related]
19. Frequency of Bevacizumab and Ranibizumab Injections for Diabetic Macular Edema in Medicare Beneficiaries.
Wu CM; Wu AM; Greenberg PB; Yu F; Lum F; Coleman AL
Ophthalmic Surg Lasers Imaging Retina; 2018 Apr; 49(4):241-244. PubMed ID: 29664980
[TBL] [Abstract][Full Text] [Related]
20. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
